GlassScriptPhysician profile
Kevin Daniel Lanclos
NPI 1841297793
$3,991.43
in general payments reported to CMS, 2019-2025
37 companies · $859 in 2025
The $859 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $402 · 2021: $342 · 2022: $397 · 2023: $683 · 2024: $848 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324 · Education: $65.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.26 |
| Education | $65.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $533.41 | 2019-2025 | |
| Lilly USA, LLC | $482.84 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $458.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $428.28 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $225.70 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.70 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $151.75 | 2020-2025 | Gardasil 9, Capvaxive, Gardasil |
| Janssen Pharmaceuticals, INC | $149.85 | 2020-2024 | Xarelto, Spravato |
| Exact Sciences Corporation | $149.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $123.49 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $113.12 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.87 | 2019-2024 | Xifaxan, Trulance |
| Dexcom, INC. | $91.43 | 2023-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $91.42 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.39 | 2021-2024 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Lanclos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.